We next retrospectively examined the impact of HSP90 expression on progression-free survival and overall survival (PFS and OS) of 72 patients with HER2+ breast cancer undergoing first-line treatment for metastatic disease with either trastuzumab plus chemotherapy or combined trastuzumab/pertuzumab plus chemotherapy. This evidence concerns the gene HSP90AA1 and breast carcinoma.